Next generation of adenoassociated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 22, (7827-7832) DOI: 10.1073/pnas.0802866105);Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 22, 2008, Pages 7827-7832

  Zhong, Li ^a,b   Li, Baozheng ^a   Mah, Cathryn S ^a   Govindasamy, Lakshmanan ^a   Agbandje McKenna, Mavis ^a   Cooper, Mario ^a   Herzog, Roland W ^a   Zolotukhin, Irene ^a   Warrington Jr , Kenneth H ^a   Weigel Van Aken, Kirsten A ^a,b   Hobbs, Jacqueline A ^a,b   Zolotukhin, Sergei ^a   Muzyczka, Nicholas ^a   Srivastava, Arun ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

AAV vectors; Capsid mutations; Gene expression; Gene therapy; Gene transfer

Indexed keywords

BLOOD CLOTTING FACTOR 9; ENHANCED GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; TYROSINE;

ADENO ASSOCIATED VIRUS 2; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PARVOVIRUS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; UBIQUITINATION; VIRUS CAPSID; ADENO ASSOCIATED VIRUS; ANIMAL; C57BL MOUSE; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; PHOSPHORYLATION;

ADENO-ASSOCIATED VIRUS - 2; MIRIDAE; MURINAE;

ANIMALS; CAPSID; CELL NUCLEUS; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HEPATOCYTES; HUMANS; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; POINT MUTATION; TRANSDUCTION, GENETIC; TYROSINE; UBIQUITINATION;

EID: 45549090635     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0806067105     Document Type: Erratum

References (50)

1. Berns KI, Giraud C (1996) Biology of adeno-associated virus. Curr Top Microbiol Immunol 218:1-23.
2. Muzyczka N (1992) Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158:97-129.
3. Flotte TR, et al. (1993) Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 90:10613-10617.
4. Snyder RO, et al. (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 16:270-276.
5. Xiao X, Li J, Samulski RJ (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098-8108.
6. Flotte T, et al. (1996) A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 7:1145-1159.
7. Kay MA, et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24:257-261.
8. Flotte TR, et al. (2004) Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 15:93-128.
9. Snyder RO, Francis J (2005) Adeno-associated viral vectors for clinical gene transfer studies. Curr Gene Ther 5:311-321.
10. Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438-1445.
11. Qing K, et al. (1999) Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5:71-77.
12. Summerford C, Bartlett JS, Samulski RJ (1999) AlphaVbeta5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med 5:78-82.
13. Kashiwakura Y, et al. (2005) Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79:609-614.
14. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A (2000) Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 74:992-996.
15. Hansen J, Qing K, Srivastava A (2001) Adeno-associated virus type 2-mediated gene transfer: Altered endocytic processing enhances transduction efficiency in murine fibroblasts. J Virol 75:4080-4090.
16. Sanlioglu S, et al. (2000) Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 74:9184-9196.
17. Douar AM, Poulard K, Stockholm D, Danos O (2001) Intracellular trafficking of adeno-associated virus vectors: Routing to the late endosomal compartment and proteasome degradation. J Virol 75:1824-1833.
18. Zhao W, et al. (2006) Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology 353:283-293.
19. Thomas CE, Storm TA, Huang Z, Kay MA (2004) Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78:3110-3122.
20. Zhong L, et al. (2004) Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. Hum Gene Ther 15:1207-1218.
21. Ferrari FK, Samulski T, Shenk T, Samulski RJ (1996) Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 70:3227-3234.
22. Fisher KJ, et al. (1996) Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70:520-532.
23. Qing K, et al. (2001) Adeno-associated virus type 2-mediated gene transfer: Role of cellular FKBP52 protein in transgene expression. J Virol 75:8968-8976.
24. Zhong L, et al. (2004) Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90. J Biol Chem 279:12714-12723.
25. Zhong L, et al. (2004) Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo. Gene Ther 11:1165-1169.
26. Zhong L, et al. (2004) Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. Mol Ther 10:950-957.
27. Zhong L, et al. (2008) Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. Mol Ther 16:290-295.
28. Tan M, Qing K, Zhou S, Yoder MC, Srivastava A (2001) Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. Mol Ther 3:940-946.
29. Zhong L, et al. (2006) Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5. Hum Gene Ther 17:321-333.
30. McCarty DM, Young SM, Jr, Samulski RJ (2004) Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 38:819-845.
31. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF (2000) Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 105:1573-1587.
32. Ding W, Zhang LN, Yeaman C, Engelhardt JF (2006) rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 13:671-682.
33. Zhong L, et al. (2007) A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther 15:1323-1330.
34. Zhong L, et al. (2007) Tyrosine-phosphorylation of AAV2 capsid proteins and its consequences on viral intracellular trafficking and transgene expression. Mol Ther 15S:149.
35. Xiao W, Warrington KH, Jr, Hearing P, Hughes J, Muzyczka N (2002) Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol 76:11505-11517.
36. Qing K, et al. (1997) Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression. Proc Natl Acad Sci USA 94:10879-10884.
37. Mah C, et al. (1998) Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J Virol 72:9835-9843.
38. Yan Z et al. (2002) Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol 76:2043-2053.
39. Pajusola K, et al. (2002) Cell-type-specific characteristics modulate the transduction efficiency of adeno-associated virus type 2 and restrain infection of endothelial cells. J Virol 76:11530-11540.
40. Yan Z, et al. (2004) Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 78:2863-2874.
41. Warrington KH, Jr, Herzog RW (2006) Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 119:571-603.
42. Manno CS, et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347.
43. Mingozzi F, et al. (2007) CD8(+) T cell responses to adeno-associated virus capsid in humans. Nat Med 13:419-422.
44. Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM (2001) Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gene Ther 12:71-76.
45. Xie Q, et al. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 99:10405-10410.
46. Jones TA, Zou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47 (Pt 2):110-119.
47. Emsley P, Cowtan K (2004) COOT: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
48. Wang W, Malcolm BA (1999) Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange site-directed mutagenesis. Biotechniques 26:680-682.
49. 2+- calmodulin-dependent protein kinase II via MAP kinase signaling in cultured vascular smooth muscle cells. Anesthesiology 96:148-154.
50. Mingozzi F, et al. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111:1347-1356.